Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. November 2019 08:00 ET | Quelle: Optinose, Inc.

Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019

YARDLEY, Pa., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
04. Oktober 2019 08:00 ET | Quelle: Optinose, Inc.

Optinose Appoints Michael Richardson to New Position of Vice President, Business Development

YARDLEY, Pa., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported...
27. September 2019 08:00 ET | Quelle: Optinose, Inc.

Optinose to Present at the 2019 Cantor Global Healthcare Conference

YARDLEY, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
26. September 2019 07:00 ET | Quelle: Optinose, Inc.

OptiNose Announces License Agreement Related to ONZETRA XSAIL

YARDLEY, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OptiNose, Inc. (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists,...
17. September 2019 16:01 ET | Quelle: Optinose, Inc.

Optinose Announces Departure of Chief Commercial Officer

YARDLEY, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
12. September 2019 16:05 ET | Quelle: Optinose, Inc.

Optinose Announces $150 Million Debt Financing from Pharmakon

YARDLEY, Pa., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported...
12. August 2019 16:02 ET | Quelle: Optinose, Inc.

Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

XHANCE net revenue grew 68% to $6.7 million from first to second quarter 2019 XHANCE prescriptions increased 51% from first to second quarter 2019 Company expects XHANCE net revenues for 2019 to be...
01. August 2019 16:30 ET | Quelle: Optinose, Inc.

Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019

YARDLEY, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
20. Juni 2019 08:00 ET | Quelle: Optinose, Inc.

Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

YARDLEY, Pa., June 20, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
19. Juni 2019 16:30 ET | Quelle: Optinose, Inc.

Optinose Named a 2019 Best Place to Work by Philadelphia Business Journal

YARDLEY, Pa., June 19, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...

Vorherige Seite